American Journal of Cardiology
Volume 101, Issue 12, Supplement , Pages S1-S2 , 16 June 2008

Introduction

  • Michael H. Davidson, MD

      Affiliations

    • Corresponding Author InformationAddress for reprints: Michael H. Davidson, MD, Preventive Cardiology Center, University of Chicago Pritzker School of Medicine, 515 North State Street, Suite 2700, Chicago, Illinois 60610.

References 

  1. Menotti A, Lanti M, Kromhout D, Blackburn H, Nissinen A, Dontas A, et al. Forty-year coronary mortality trends and changes in major risk factors in the first 10 years of follow-up in the seven countries study. Eur J Epidemiol. 2007;22:747–754
  2. Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005;96(suppl):3K–13Kdiscussion 34K–35K
  3. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716
  4. Ridker PM. High sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J. 2004;148(1 Suppl):S19–S26
  5. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007;82:159–165

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(08)00683-8

doi: 10.1016/j.amjcard.2008.04.012

American Journal of Cardiology
Volume 101, Issue 12, Supplement , Pages S1-S2 , 16 June 2008

Article Tools